Anti-NMDA receptor encephalitis classification

Revision as of 05:49, 13 May 2023 by Dj (talk | contribs) (→‎References)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Anti-NMDA receptor encephalitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Anti-NMDA receptor encephalitis from Other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Anti-NMDA receptor encephalitis classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Anti-NMDA receptor encephalitis classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Anti-NMDA receptor encephalitis classification

CDC on Anti-NMDA receptor encephalitis classification

Anti-NMDA receptor encephalitis classification in the news

Blogs on Anti-NMDA receptor encephalitis classification

Directions to Hospitals Treating Anti-NMDA receptor encephalitis

Risk calculators and risk factors for Anti-NMDA receptor encephalitis classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; AE Dheeraj Makkar, M.D.[2]

Overview

Anti-NMDA encephalitis can be categorized into three distinct subtypes based on the timing of onset and duration of the illness.

Classification

Anti NMDA Encephalitis may be classified into three subtypes, depending on the timing of presentation and duration.


Subtype Symptoms Duration
Class 1 Primarily catatonic or stuporous state Less than 60 days
Class 2 Primarily psychotic state More than 60 days
Class 3 Primarily catatonic or stuporous state More than 60 days

References

[1] Template:WH Template:WS

  1. Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F; et al. (2014). "Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study". Lancet Neurol. 13 (2): 167–77. doi:10.1016/S1474-4422(13)70282-5. PMC 4006368. PMID 24360484.